Market Overview

UPDATE: Credit Suisse Initiates Genomic Health at Outperform on Growth Potential

Related GHDX
Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer
Oncotype DX Predicts Outcomes In Prostate Cancer Patients, Significantly Changes Treatment Recommendations

Credit Suisse initiated coverage on Genomic Health (NASDAQ: GHDX) with an Outperform rating and a $43 price target.

Credit Suisse said, "Genomic Health's stock has steadily appreciated over the past two years due to the success of its Oncotype DX cancer assays. We believe that the trend should continue as the company captures incremental market share with its already-established tests in breast and colon cancer and launches tests in new markets such as prostate cancer."

Genomic Health closed at $36.15 on Monday.

Latest Ratings for GHDX

DateFirmActionFromTo
Nov 2014Credit SuisseMaintainsNeutral
Nov 2014Bank of AmericaMaintainsUnderperform
Nov 2014Canaccord GenuityMaintainsHold

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GHDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters